Olema Pharmaceuticals, Inc. (OLMA)
NASDAQ: OLMA · Real-Time Price · USD
11.39
-0.04 (-0.35%)
At close: Jun 26, 2026, 4:00 PM EDT
11.17
-0.22 (-1.93%)
After-hours: Jun 26, 2026, 5:08 PM EDT
Olema Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Olema Pharmaceuticals stock have an average target of 39.44, with a low estimate of 23 and a high estimate of 62. The average target predicts an increase of 246.27% from the current stock price of 11.39.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Olema Pharmaceuticals stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 10 | 10 | 10 | 10 | 9 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 13 | 13 | 13 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 9, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $29 → $24 | Buy | Maintains | $29 → $24 | +110.71% | Jun 6, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $38 | Buy | Reiterates | $38 | +233.63% | Jun 3, 2026 |
| UBS | UBS | Buy Maintains $45 | Buy | Maintains | $45 | +295.08% | Jun 2, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $38 → $35 | Buy | Maintains | $38 → $35 | +207.29% | Jun 1, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
23.12M
EPS This Year
-2.27
from -1.87
EPS Next Year
-2.48
from -2.27
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | 41.4M | |
| Avg | n/a | 23.1M | |
| Low | n/a | 3.0M |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | 829.8% |
| Avg | - | 472.4% |
| Low | - | 278.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.95 | -1.81 | |
| Avg | -2.27 | -2.48 | |
| Low | -2.62 | -3.04 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.